Better adherence to PrEP is associated with more bone loss
Injectable cabotegravir plus rilpivirine every two months maintains viral suppression for three years, but carries higher risk of treatment failure
Higher risks of cancer for Black men with HIV suggest racial inequities in US health care
Long COVID more common in people with HIV
Knowledge of U=U alone is unlikely to eradicate HIV stigma among gay and bisexual men in India, anthropologist argues
Top 5 HIV treatment stories from CROI 2022
Top 5 HIV cure and vaccine stories from CROI 2022
Top 5 stories on HIV prevention from CROI 2022
Top 5 stories on HIV, ageing and co-morbidities from CROI 2022
